Micronose develops a personalized allergy therapy utilizing probiotic strains derived from healthy human microbiomes to restore immune balance. The company targets allergic reactions by leveraging specific Bifidobacterium strains that modulate immune responses and reduce pro-allergic cytokine levels.
Funding
$6.4K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Allergic reactions stem from an imbalance in the immune system, often triggered by environmental factors or specific allergens. Current treatments primarily focus on managing symptoms rather than addressing the underlying cause of the allergic response. Traditional allergy therapies may not provide long-term relief and can have undesirable side effects.
Solution
Micronose is developing personalized allergy therapies using probiotic strains derived from healthy human microbiomes to restore immune balance. The company leverages specific *Bifidobacterium* strains, including *Bifidobacterium adolescentis* CCDM 368 and *Bifidobacterium longum* ssp. *longum* CCM 7952, to modulate immune responses and reduce pro-allergic cytokine levels. These strains have demonstrated the ability to decrease levels of pro-allergic cytokines and IgE antibodies, as well as strengthen the intestinal barrier. Micronose's approach involves identifying and utilizing beneficial bacteria to create targeted interventions that address the root cause of allergies. The company aims to develop personalized therapies based on individual microbiome analysis.
Target Audience
The primary target audience includes individuals suffering from allergies and seeking natural, long-term solutions to restore immune balance, as well as healthcare professionals specializing in allergy treatment and immunology.
Features
- Utilizes *Bifidobacterium adolescentis* CCDM 368, which produces a polysaccharide that reduces pro-allergic cytokine levels (interleukin 5 and 13).
- Incorporates *Bifidobacterium longum* ssp. *longum* CCM 7952, shown to reduce eosinophil levels and pro-allergic cytokines in lung models.
- Employs probiotic strains derived from healthy human flora to restore the natural balance of the immune system.
- Focuses on addressing the underlying causes of allergies rather than just managing symptoms.
- Developing personalized allergy therapies based on individual microbiome analysis.